Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emergent Biosolutions ( (EBS) ) just unveiled an announcement.
Emergent BioSolutions reported its financial results for the second quarter of 2025, with total revenues of $140.9 million, surpassing guidance by $21 million. Despite a net loss of $12 million, the company showed significant improvements in profitability and margins compared to the previous year. The company raised its full-year profitability guidance and secured several government contracts, reinforcing its position in the medical countermeasures market.
The most recent analyst rating on (EBS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.
Spark’s Take on EBS Stock
According to Spark, TipRanks’ AI Analyst, EBS is a Neutral.
Emergent BioSolutions faces substantial financial challenges, as reflected by declining revenues and profitability issues, which significantly impact its stock score. Technical indicators further highlight bearish momentum. While recent earnings showed improvements in net income and margin expansion, ongoing revenue decline and legal uncertainties weigh on the outlook.
To see Spark’s full report on EBS stock, click here.
More about Emergent Biosolutions
Emergent BioSolutions is a company operating in the biopharmaceutical industry, focusing on medical countermeasures. Its primary products include NARCAN® Nasal Spray for opioid overdose and various biodefense products like anthrax and smallpox medical countermeasures. The company is known for its leadership in medical countermeasures with government stakeholders.
Average Trading Volume: 1,291,543
Technical Sentiment Signal: Sell
Current Market Cap: $331.1M
Learn more about EBS stock on TipRanks’ Stock Analysis page.